BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139]
URL: https://www.wjgnet.com/1007-9327/full/v20/i5/1139.htm
Number Citing Articles
1
Lindsay Hahn, Ashton Beggs, Kristy Wahaib, Leela Kodali, Vanessa Kirkwood. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitisAmerican Journal of Health-System Pharmacy 2015; 72(15): 1271 doi: 10.2146/ajhp140449
2
Javier P. Gisbert, María Chaparro. Ustekinumab to treat Crohn's diseaseGastroenterología y Hepatología (English Edition) 2017; 40(10): 688 doi: 10.1016/j.gastre.2017.08.003
3
Raewyn M. Poole. Vedolizumab: First Global ApprovalDrugs 2014; 74(11): 1293 doi: 10.1007/s40265-014-0253-1
4
Diego Currò, Gianluca Ianiro, Silvia Pecere, Stefano Bibbò, Giovanni Cammarota. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disordersBritish Journal of Pharmacology 2017; 174(11): 1426 doi: 10.1111/bph.13632
5
Ryan Marshall, Ian Taylor, Christopher Lahr, Thomas L. Abell, Ingrid Espinoza, Nitin K. Gupta, Christian R. Gomez. Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel DiseaseClinical Medicine Insights: Gastroenterology 2015; 8: CGast.S31779 doi: 10.4137/CGast.S31779
6
Javier P. Gisbert, Eugeni Domènech. Vedolizumab en el tratamiento de la enfermedad de CrohnGastroenterología y Hepatología 2015; 38(5): 338 doi: 10.1016/j.gastrohep.2014.12.003
7
M. V. Shapina, B. A. Nanaeva, A. V. Vardanyan. EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (reviewKoloproktologia 2019; 18(3(69)): 119 doi: 10.33878/2073-7556-2019-18-3-119-130
8
Javier P. Gisbert, María Chaparro. Ustekinumab en el tratamiento de la enfermedad de CrohnGastroenterología y Hepatología 2017; 40(10): 688 doi: 10.1016/j.gastrohep.2017.08.006